Abstract

The global life sciences industry has a profound opportunity to promote patient-centrity and stimulate greater collaboration with patients, patient advocacy groups, communities, providers, and payers by embracing the growing Food as Medicine (FAM) movement, which is a subset of the broader social determinants of health (SDOH) framework. As part of a strategic shift to think more wholistically about health, food can be used to improve drug discovery, development, and deployment, as well as build partnerships between biopharmaceutical companies and key stakeholders in the healthcare ecosystem. We examine the conceptual and practical implementation dimensions of how the life sciences can fully leverage food as medicine to advance clinical, medical, regulatory, and policy objectives. This includes leveraging health economics and outcomes research (HEOR), real-world data (RWD), and real-world evidence (RWE) to enhance FAM and SDOH strategies for improving drug discovery, development, and deployment.

This work is licensed under a Creative Commons Attribution 4.0 License.